Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 14/20 | 0.49 |
| ▸ | GSK3B | P49841 | 14/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 9/20 | 0.49 |
| ▸ | CDK5R1 | Q15078 | 9/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.48 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 3/20 | 0.45 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.43 |
| ▸ | CDK1 | P06493 | 2/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.43 |
| ▸ | CDK2 | P24941 | 2/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.43 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL680301 | 0.84 | GSK3A (0.46) | GSK3AGSK3BCDK5CDK5R1NPC1 | |
| SCHEMBL5826323 | 0.83 | GSK3A (0.57) | GSK3AGSK3BCDK5CDK5R1KDR | |
| SCHEMBL30493623 | 0.79 | NPC1 (0.50) | GSK3AGSK3BCDK5CDK5R1NPC1 | |
| SCHEMBL2233893 | 0.79 | NPC1 (0.50) | GSK3AGSK3BCDK5CDK5R1NPC1 | |
| SCHEMBL291842 | 0.77 | MEN1 (0.44) | GSK3AGSK3BCDK5CDK5R1NPC1 | |
| SCHEMBL379447 | 0.75 | ALDH1A1 (0.42) | GSK3AGSK3BCDK5CDK5R1NPC1 | |
| SCHEMBL379446 | 0.75 | ALDH1A1 (0.42) | GSK3AGSK3BCDK5CDK5R1NPC1 | |
| SCHEMBL20414232 | 0.74 | KMT2A (0.39) | GSK3AGSK3BCDK5CDK5R1ABL1 | |
| SCHEMBL3053419 | 0.73 | MAPT (0.53) | GSK3AGSK3BCDK5CDK5R1NPC1 | |
| SCHEMBL1185191 | 0.73 | CYP1A2 (0.49) | GSK3BCDK5CDK5R1NPC1CCNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879591-B1 | USE OF AZAPAULLONES FOR PREVENTING AND TREATING PANCREATIC AUTOIMMUNE DISORDERS | DEVELOGEN AG (DE) | 2012-01-25 | — | — | EP | disclosed |
| US-7968535-B2 | Antidiabetic agents; neurodegenerative disorders; mixture with immunosuppresants | DEVELOGEN ATKIENGESELLSCHAFT (DE) | 2011-06-28 | — | — | US | disclosed |
| US-20080287423-A1 | Use of Azapaullones For Preventing and Treating Pancreatic Autoimmune Disorders | EVOTEC INTERNATIONAL GMBH (DE) | 2008-11-20 | — | — | US | disclosed |
| EP-1879591-A1 | USE OF AZAPAULLONES FOR PREVENTING AND TREATING PANCREATIC AUTOIMMUNE DISORDERS | DeveloGen Aktiengesellschaft (DE) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006117221-A1 | USE OF AZAPAULLONES FOR PREVENTING AND TREATING PANCREATIC AUTOIMMUNE DISORDERS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287423-A1 | Use of Azapaullones For Preventing and Treating Pancreatic Autoimmune Disorders | IAPP, RNASE1, AMY2A | GSK3A 1819/4885GSK3B 2669/4885CDK5 2145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.